NR4A1 and breast cancer: Three CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) are FDA-approved to treat advanced-stage or metastatic, hormone-receptor-positive, HER2-negative breast cancer (BC) (Fig. 2).